Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • Esophageal Cancer
  • Glioblastoma
  • Magnetic Resonance Imaging
  • MRI
  • Prostate Cancer
  • Radiotherapy
  • Vulvar Cancer
Type
Interventional
Phase
Not Applicable
Design
Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Other

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

This phase 1, non randomized open label study, evaluating feasibility of serial MRI, with an option for an expansion cohort. The optional expansion cohort is a prospective imaging registry evaluating imaging biomarkers as predictors of disease control with standard of care treatment. This research s...

This phase 1, non randomized open label study, evaluating feasibility of serial MRI, with an option for an expansion cohort. The optional expansion cohort is a prospective imaging registry evaluating imaging biomarkers as predictors of disease control with standard of care treatment. This research study is a feasibility study, which means it is the first-time investigators at this institution are examining the process of getting multiple MRIs during radiation treatment. The U.S. Food and Drug Administration (FDA) has cleared this MRI scanner for use. Participants who fulfill eligibility criteria will be entered into the trial. The research study procedures include: Screening for eligibility Three MRI scans (Imaging with MRI will be performed as per disease site standards.) A total of 86 participants will be enrolled in this trial Phase 1 20 participants in Esophageal Cohort 20 Participants in Glioblastoma Cohort Expansion Cohort --- 46 Participants in the Glioblastoma Expansion Cohort

Tracking Information

NCT #
NCT04188535
Collaborators
Not Provided
Investigators
Principal Investigator: Lisa Singer, MD, PhD Dana-Farber Cancer Institute